INM SEC Filing News — InMed Pharmaceuticals Inc.

Latest SEC filings for InMed Pharmaceuticals Inc. (INM) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporat…
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $7.5M
20
Total Filings
9
Bullish Classifications
0
Bearish Classifications
9
Insider Transactions
9
Material Events (8-K)
2
Periodic Reports
Rule-based classifications for INM currently lean bullish. Of the 20 displayed SEC filing records, 9 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 9 insider transactions (Form 4) in this period.
INM Filing Activity Snapshot 2026-04-03 — 2026-10-15
Insider Transactions (Form 4)
9 buys vs 0 sells
Net insider buying in this period — more purchases than sales reported.
Largest Form 144 Filing
$721.5K
ADAR1 Capital Management, LLC (10% Owner) · 2026-05-21
468,551 shares · Form 4
Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for InMed Pharmaceuticals Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 9 open-market purchase. 9 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×9
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market purchase Insider Buying 2026-10-15

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 9,569 shares (~$12.7K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 9,569 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 564 $1.33 $750.12
P Open-market purchase 8,021 $1.33 $10.7K
P Open-market purchase 984 $1.32 $1.3K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 9,569 Est. Value: $12.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-10-08

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 10,903 shares (~$14.5K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 10,903 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 5,601 $1.33 $7.4K
P Open-market purchase 3,046 $1.33 $4.1K
P Open-market purchase 2,256 $1.33 $3.0K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 10,903 Est. Value: $14.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-10-05

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 42,920 shares (~$57.1K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 42,920 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 16,431 $1.33 $21.8K
P Open-market purchase 8,307 $1.33 $11.0K
P Open-market purchase 18,182 $1.33 $24.2K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 42,920 Est. Value: $57.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-09-16

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 91,101 shares (~$118.1K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 91,101 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 28,505 $1.29 $36.9K
P Open-market purchase 54,256 $1.30 $70.4K
P Open-market purchase 8,340 $1.29 $10.8K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 91,101 Est. Value: $118.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-07-17

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 1,000 shares (~$1.6K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 1,000 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 1,000 $1.55 $1.6K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 1,000 Est. Value: $1.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-07-16

INM insider Vivo Opportunity, LLC (10% Owner) bought 20,546 shares (~$31.8K)

Vivo Opportunity, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 20,546 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 4,882 $1.55 $7.6K
P Open-market purchase 493 $1.55 $764.15
P Open-market purchase 13,761 $1.55 $21.3K
P Open-market purchase 1,389 $1.55 $2.2K
P Open-market purchase 19 $1.55 $29.45
P Open-market purchase 2 $1.55 $3.10
Filing: Form 4 (Insider Transaction) Insider: Vivo Opportunity, LLC (10% Owner) Shares: 20,546 Est. Value: $31.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-07-02

INM insider Vivo Opportunity, LLC (10% Owner) bought 6,551 shares (~$10.1K)

Vivo Opportunity, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 6,551 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 545 $1.54 $839.30
P Open-market purchase 55 $1.54 $84.70
P Open-market purchase 3,946 $1.55 $6.1K
P Open-market purchase 398 $1.55 $616.90
P Open-market purchase 1,460 $1.55 $2.3K
P Open-market purchase 147 $1.55 $227.85
Filing: Form 4 (Insider Transaction) Insider: Vivo Opportunity, LLC (10% Owner) Shares: 6,551 Est. Value: $10.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-06-10

INM insider Vivo Opportunity, LLC (10% Owner) bought 249,227 shares (~$391.6K)

Vivo Opportunity, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 249,227 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 51,056 $1.56 $79.6K
P Open-market purchase 5,154 $1.56 $8.0K
P Open-market purchase 30,882 $1.69 $52.2K
P Open-market purchase 3,118 $1.69 $5.3K
P Open-market purchase 16,164 $1.57 $25.4K
P Open-market purchase 1,632 $1.57 $2.6K
P Open-market purchase 14,838 $1.55 $23.0K
P Open-market purchase 1,498 $1.55 $2.3K
P Open-market purchase 20,753 $1.52 $31.5K
P Open-market purchase 2,095 $1.52 $3.2K
P Open-market purchase 7,069 $1.55 $11.0K
P Open-market purchase 714 $1.55 $1.1K
P Open-market purchase 6,125 $1.57 $9.6K
P Open-market purchase 618 $1.57 $970.26
P Open-market purchase 49,966 $1.57 $78.4K
P Open-market purchase 5,045 $1.57 $7.9K
P Open-market purchase 29,518 $1.52 $44.9K
P Open-market purchase 2,982 $1.52 $4.5K
Filing: Form 4 (Insider Transaction) Insider: Vivo Opportunity, LLC (10% Owner) Shares: 249,227 Est. Value: $391.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-05-21

INM insider ADAR1 Capital Management, LLC (10% Owner) bought 468,551 shares (~$721.5K)

ADAR1 Capital Management, LLC, listed as 10% Owner at InMed Pharmaceuticals Inc., reported an open-market purchase of 468,551 INM shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 68,551 $1.60 $109.7K
P Open-market purchase 200,000 $1.56 $312.1K
P Open-market purchase 200,000 $1.50 $299.8K
Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 468,551 Est. Value: $721.5K
View on SEC EDGAR → Open Filing Document →
Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for InMed Pharmaceuticals Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-18

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-22

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-10

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-10

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-19

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-19

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-07

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-27

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-03

INM filed 8-K — material company event

InMed Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 1 quarterly report (10-Q) for InMed Pharmaceuticals Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-K Annual Report 2026-09-09

INM filed Annual Report (10-K)

InMed Pharmaceuticals Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-05-06

INM filed Quarterly Report (10-Q)

InMed Pharmaceuticals Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify InMed Pharmaceuticals Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on INM. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — INM SEC Filings

More Tools for INM

INM Full Stock Analysis INM Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper INM analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the INM stock analysis page.

INM Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer